Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 2 — A. Title: All-cause mortality was significantly lower in the SGLT2 inhibitor group. Legend: There was a significant 14% relative risk reduction in all-cause mortality among patients with HF treated with SGLT2 inhibitors compared with placebo (OR 0•86; 95% CI 0•79–0•94). B. Title: Cardiovascular mortality was significantly lower in the SGLT2 inhibitor group. Legend: There was a significant 14% relative risk reduction in cardiovascular mortality among patients with HF treated with SGLT2 inhibitors compared with placebo (OR 0•86; 95% CI 0•78–0•96).